<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>D-206213ME</udiDi>
    <basicUdiDi>B-206213ME</basicUdiDi>
    <tradeName>FIDIAL PLUS</tradeName>
    <deviceName>FIDIAL PLUS</deviceName>
    <manufacturerName>Fidia Farmaceutici S.p.A.</manufacturerName>
    <manufacturerSrn>IT-MF-000026988</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>206213</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-11T11:28:17.341Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-18906040830067PN</udiDi>
    <basicUdiDi>B-18906040830067PN</basicUdiDi>
    <tradeName>(1) 1A1 AaproMel, (2) Optavid, (3) eyeon Hypromellose, (4) AacuLose, (5) lumecare Hypromellose, (6) FRESH EYE DROP, (7) PharmaBoost Hypromellose 0.3%</tradeName>
    <deviceName>Sterile Hydroxy Propyl Methyl Cellulose Eye Drops 0.3% w/v</deviceName>
    <manufacturerName>Amanta Healthcare Limited</manufacturerName>
    <manufacturerSrn>IN-MF-000034912</manufacturerSrn>
    <authorisedRepresentativeName>CMC Medical Devices &amp; Drugs SL</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>ES-AR-000000293</authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030399</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, VISCOELASTIC FLUIDS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1220855</reference>
    <placedOnMarketCountry>Spain</placedOnMarketCountry>
    <lastUpdated>2026-07-11T10:58:14.242Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-18906040830057PK</udiDi>
    <basicUdiDi>B-18906040830057PK</basicUdiDi>
    <tradeName>(1) Optavid Advance, (2) 1A1 AaqEye HA, (3) eyeon Hyaluronic, (4) Xailin HA, (5) Aactive HA, (6) HYALU TEARS Eye Drop</tradeName>
    <deviceName>Sodium Hyaluronate Eye Drops 0.2%w/v</deviceName>
    <manufacturerName>Amanta Healthcare Limited</manufacturerName>
    <manufacturerSrn>IN-MF-000034912</manufacturerSrn>
    <authorisedRepresentativeName>CMC Medical Devices &amp; Drugs SL</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>ES-AR-000000293</authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1220853</reference>
    <placedOnMarketCountry>Spain</placedOnMarketCountry>
    <lastUpdated>2026-07-11T10:58:12.955Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-18906040830037PD</udiDi>
    <basicUdiDi>B-18906040830037PD</basicUdiDi>
    <tradeName>(1) 1A1 AaqEye,(2) Aqualube,(3) eyeon DUE-Carmellose,(4) ARTI-TEARS Eye Drop, (5) Carmellose Alissa</tradeName>
    <deviceName>Carboxy Methyl Cellulose Eye Drops</deviceName>
    <manufacturerName>Amanta Healthcare Limited</manufacturerName>
    <manufacturerSrn>IN-MF-000034912</manufacturerSrn>
    <authorisedRepresentativeName>CMC Medical Devices &amp; Drugs SL</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>ES-AR-000000293</authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030399</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, VISCOELASTIC FLUIDS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1220854</reference>
    <placedOnMarketCountry>Spain</placedOnMarketCountry>
    <lastUpdated>2026-07-11T10:58:12.157Z</lastUpdated>
  </row>
  <row>
    <udiDi>18021118001429</udiDi>
    <basicUdiDi>B-18021118001429</basicUdiDi>
    <tradeName>Ocigel</tradeName>
    <deviceName>Ocigel</deviceName>
    <manufacturerName>AL.CHI.MI.A. S.R.L.</manufacturerName>
    <manufacturerSrn>IT-MF-000028901</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf I</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030399</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, VISCOELASTIC FLUIDS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>OCI 001</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-11T07:16:55.816Z</lastUpdated>
  </row>
  <row>
    <udiDi>18021118001467</udiDi>
    <basicUdiDi>B-18021118001467</basicUdiDi>
    <tradeName>eyeDRO</tradeName>
    <deviceName></deviceName>
    <manufacturerName>AL.CHI.MI.A. S.R.L.</manufacturerName>
    <manufacturerSrn>IT-MF-000028901</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>Q02030399</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, VISCOELASTIC FLUIDS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>EDO 002</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-11T07:16:55.769Z</lastUpdated>
  </row>
  <row>
    <udiDi>18021118001153</udiDi>
    <basicUdiDi>B-18021118001153</basicUdiDi>
    <tradeName>eyeDRO</tradeName>
    <deviceName></deviceName>
    <manufacturerName>AL.CHI.MI.A. S.R.L.</manufacturerName>
    <manufacturerSrn>IT-MF-000028901</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>Q02030399</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, VISCOELASTIC FLUIDS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>EDO 001</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-11T07:16:33.928Z</lastUpdated>
  </row>
  <row>
    <udiDi>17350030051894</udiDi>
    <basicUdiDi>B-17350030051894</basicUdiDi>
    <tradeName>Minivisc</tradeName>
    <deviceName>Minivisc Plus</deviceName>
    <manufacturerName>Bohus BioTech AB</manufacturerName>
    <manufacturerSrn>SE-MF-000037369</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>-</reference>
    <placedOnMarketCountry>Sweden</placedOnMarketCountry>
    <lastUpdated>2026-07-11T07:14:00.919Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-1300141954</udiDi>
    <basicUdiDi>B-1300141954</basicUdiDi>
    <tradeName>FIDIAL PLUS</tradeName>
    <deviceName>FIDIAL PLUS</deviceName>
    <manufacturerName>Fidia Farmaceutici S.p.A.</manufacturerName>
    <manufacturerSrn>IT-MF-000026988</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>13001419</reference>
    <placedOnMarketCountry>Romania</placedOnMarketCountry>
    <lastUpdated>2026-07-11T02:57:25.398Z</lastUpdated>
  </row>
  <row>
    <udiDi>04250906200042</udiDi>
    <basicUdiDi>425090620HA-OVDUG</basicUdiDi>
    <tradeName>VisOcu</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Phibio GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000045435</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>PHI141DE-VSO</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-11T01:28:16.113Z</lastUpdated>
  </row>
  <row>
    <udiDi>04250906200059</udiDi>
    <basicUdiDi>425090620HA-OVDUG</basicUdiDi>
    <tradeName>VisOcu</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Phibio GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000045435</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>PHI161DE-VSO</reference>
    <placedOnMarketCountry>Greece</placedOnMarketCountry>
    <lastUpdated>2026-07-11T01:28:16.099Z</lastUpdated>
  </row>
  <row>
    <udiDi>04250906200066</udiDi>
    <basicUdiDi>425090620HA-OVDUG</basicUdiDi>
    <tradeName>VisOcu</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Phibio GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000045435</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>PHI181DE-VSO</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-11T01:28:16.079Z</lastUpdated>
  </row>
  <row>
    <udiDi>04250906200073</udiDi>
    <basicUdiDi>425090620HA-OVDUG</basicUdiDi>
    <tradeName>VisOcu</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Phibio GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000045435</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>PHI221DE-VSO</reference>
    <placedOnMarketCountry>Greece</placedOnMarketCountry>
    <lastUpdated>2026-07-11T01:28:16.048Z</lastUpdated>
  </row>
  <row>
    <udiDi>04250906200080</udiDi>
    <basicUdiDi>425090620HA-OVDUG</basicUdiDi>
    <tradeName>VisOcu</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Phibio GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000045435</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>PHI301DE-VSO</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-11T01:28:16.019Z</lastUpdated>
  </row>
  <row>
    <udiDi>04250906200110</udiDi>
    <basicUdiDi>425090620HA-OVDUG</basicUdiDi>
    <tradeName>ViscOge</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Phibio GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000045435</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>PHI101DE-VSG</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-11T01:28:15.988Z</lastUpdated>
  </row>
  <row>
    <udiDi>04250906200127</udiDi>
    <basicUdiDi>425090620HA-OVDUG</basicUdiDi>
    <tradeName>ViscOge</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Phibio GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000045435</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>PHI141DE-VSG</reference>
    <placedOnMarketCountry>France</placedOnMarketCountry>
    <lastUpdated>2026-07-11T01:28:15.971Z</lastUpdated>
  </row>
  <row>
    <udiDi>04250906200134</udiDi>
    <basicUdiDi>425090620HA-OVDUG</basicUdiDi>
    <tradeName>ViscOge</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Phibio GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000045435</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>PHI161DE-VSG</reference>
    <placedOnMarketCountry>France</placedOnMarketCountry>
    <lastUpdated>2026-07-11T01:28:15.957Z</lastUpdated>
  </row>
  <row>
    <udiDi>04250906200141</udiDi>
    <basicUdiDi>425090620HA-OVDUG</basicUdiDi>
    <tradeName>ViscOge</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Phibio GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000045435</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>PHI181DE-VSG</reference>
    <placedOnMarketCountry>France</placedOnMarketCountry>
    <lastUpdated>2026-07-11T01:28:15.944Z</lastUpdated>
  </row>
  <row>
    <udiDi>04250906200158</udiDi>
    <basicUdiDi>425090620HA-OVDUG</basicUdiDi>
    <tradeName>ViscOge</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Phibio GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000045435</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>PHI221DE-VSG</reference>
    <placedOnMarketCountry>Greece</placedOnMarketCountry>
    <lastUpdated>2026-07-11T01:28:15.911Z</lastUpdated>
  </row>
  <row>
    <udiDi>04250906200165</udiDi>
    <basicUdiDi>425090620HA-OVDUG</basicUdiDi>
    <tradeName>ViscOge</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Phibio GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000045435</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>PHI301DE-VSG</reference>
    <placedOnMarketCountry>France</placedOnMarketCountry>
    <lastUpdated>2026-07-11T01:28:15.885Z</lastUpdated>
  </row>
</eudamedExport>